Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma

Abstract Background and Aim Molecular‐targeted therapies such as sorafenib and lenvatinib have long been used as first‐line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known a...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama, Kobe Liver Conference (KLC)
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2022-06-01
Sarja:	JGH Open
Aiheet:	hepatocellular carcinoma post‐progression therapy tyrosine kinase inhibitor
Linkit:	https://doi.org/10.1002/jgh3.12772
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!